Kronik spontan ürtikerde omalizumab tedavisinin etkinliği ve güvenliği

Amaç: Bu çalışmada antihistaminik tedavisine dirençli kronik spontan ürtikerli (KSÜ) hastalarda omalizumabın etkinliği ve güvenliğinin klinik ortamda araştırılması hedeflenmiştir.Gereç ve Yöntem: KSÜ nedeniyle takip edilen, 6 aydan daha uzun süreli antihistaminik tedavisine yanıt alınamayıp omalizumab tedavisi verilen 30 hastanın kayıtları geriye dönük olarak incelendi. Hiç ürtikeryal plağı ve kaşıntısı olmayanlar tam yanıtlı, tedavi başlangıcına göre hayat kalitesi artan ve semptomlarında belirgin iyileşme olanlar kısmi yanıtlı, semptomlarında hiç iyileşme olmayanlar yanıtsız olarak kabul edildi. Bulgular: Çalışmaya 30 KSÜ li omalizumab ile tedavi edilen hasta (kadın/erkek: 23/7) alındı. OOrtalama omalizumab tedavi süresi 10.3±4.8 (min-maks:3-21) ay idi. Omalizumab tedavisi sonrası 4 (13.3%) hastada tam yanıt, 26 (86.7%) hastada kısmı yanıt görülürken, yanıt alınamayan hasta olmadı. Omalizumab kullanımı sırasında hastalar ciddi yan etki yaşamadılar. Sadece bir (3.3%) hastada lokal eritem görüldü. Sonuç: Bu çalışmada antihistaminik tedavisine dirençli KSÜ de omalizumabın etkili ve güvenli bir tedavi olduğu gösterilmiştir.

Anahtar Kelimeler:

Kronik spontan ürtiker, ürtikerde omalizumab tedavisi, ürtikerde anti-Ig E

Safety and efficacy of omalizumab treatment in chronic spontaneous urticaria

Purpose: The aim of this study was to evaluate efficacy and safety of omalizumab therapy in patients with antihistamine resistant chronic spontaneous urticaria (CSU) presented in a clinical setting. Materials and Methods: The files of 30 CSU patients treated with omalizumab were examined. Omalizumab therapy was started to antihistamine-resistant CSU patients who treated with antihistamine therapy at least six months. The response to treatment was evaluated as follows; complete response defined as total absence of hives and itching, partial response as significant improvement in symptoms and quality of life, but still presenting hives and itching, and no response no improvement in both symptoms and quality of life.Results: In our cohort there were 30 CSU patients treated with omalizumab (women/men: 23/7). The mean (SD) duration of omalizumab treatment was 10.3 ± 4.8 (min-max:3-21) months. After omalizumab treatment, there were complete response in 4 (13.3%) patients, partly response in 26 (86.7%) patients and there were no patient with no response. Patients did not experience significantly important adverse reactions. Only one (3.3%) patient had local erythema. Conclusion: This study showed that omalizumab is a well-tolerated and effective therapy for patients with antihistamine-resistant chronic spontaneous urticaria.

Keywords:

Chronic spontaneous urticaria, omalizumab treatment in urticaria,

PDF

___

1. Greaves, M. W. Chronic urticaria. N Engl J Med. 1995;332:1767-72.
2. Greenberger PA. Chronic urticaria: new management options. World Allergy Organ J. 2014;7:31.
3. Zuberbier, T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z , Canonica GW et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868-87.
4. Grattan CE, O’Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol. 2000;143:365-72.
5. Vena GA, Cassano N, Colombo D, Peruzzi E, Pigatto P. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized placebo-controlled trial. J Am Acad Dermatol. 2006;55:705-9.
6. Doshi DR, Weinberger MM. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr Dermatol. 2009;26:409-13.
7. Chang T.W, Chen C, Lin C.J, Metz M, Church M.K, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135:337-42.
8. D’Amato G. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases. Eur J Pharmacol. 2006;533:302-7.
9. Lai T, Wang S, Xu Z, Zhang C, Zhao Y, Hu Y et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;5:8191.
10. Corren J, Casale T, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39:788-97.
11. Ensina LF, Valle SOR, Juliani AP, Galeane M, dos Santos R V, Arruda LK et al. Omalizumab in chronic spontaneous urticaria: a Brazilian real-life experience. Int Arch Allergy Immunol. 2016;169:121-4.
12. Vadasz Z, Tal Y, Rotem M, Shichter-Confino V, Mahlab-Guri K, Graif Y et al. Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients. J Allergy Clin Immunol Pract. 2017;5:1743-5.
13. Akyol A, Öktem A, Akay BN, Kundakçı N, Boyvat A. Omalizumab ve tedaviye dirençli kronik spontan ürtiker tedavisindeki yeri. Türkderm. 2015;49:180-3.
14. Maurer M, Rosen K, Hsieh HJ, Saini S, Grattan C, Gimenez-Arnau A et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924-35.
15. Metz M, Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol. 2012;12:406-11.
16. Labrador-Horrillo M, Valero A, Velasco M, Jáuregui I, Sastre J, Bartra J et al. Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opin Biol Ther. 2013;13:1225-28.
17. Kaplan A, Ferrer M, Bernstein JA, Antonova E, Trzaskoma B, Raimundo K et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016;137:474-81.
18. Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567-573.
19. Tat TS, Cilli A. Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma. Ann Allergy Asthma Immunol. 2016;117:546-9.
20. Corren J, Casale T, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39:788-97.
21. Tat TS, Cilli A. Ağır alerjik astımlı hastalarda omalizumab tedavisi. Istanbul Medical Journal. 2017;18:135-8.
22. Tat TS, Cilli A. Omalizumab treatment in asthma-COPD overlap syndrome. J Asthma. 2016;53:1048–50.
23. Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134:560-7.
24. Busse W, Buhl R, Vidaurre CF, Blogg M, Zhu J, Eisner MD et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol. 2012;129:983-9.